Iridex (IRIX) Cash from Operations Growth (3y) (2014 - 2026)

Iridex (IRIX) Cash from Operations Growth (3y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 4.78%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 9.30%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 1.51%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 22.35%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -48.14%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 50.11%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -14.75%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 0.50%
10 Iridex 15.41 Mn 10.81 Mn 4.74 Mn 22.27%

Historic Data

Download Data
DateValue
Apr 4, 2026 22.27%
Jan 3, 2026 33.33%
Sep 27, 2025 18.07%
Jun 28, 2025 46.34%
Mar 29, 2025 29.31%
Dec 28, 2024 -28.26%
Mar 30, 2024 -28.85%
Sep 30, 2023 -85.14%
Jul 1, 2023 16.87%
Apr 1, 2023 -25.07%
Dec 31, 2022 -103.38%
Oct 1, 2022 6.34%
Jul 2, 2022 -23.51%
Apr 2, 2022 5.02%
Jan 1, 2022 95.60%
Apr 3, 2021 85.06%
Sep 26, 2020 30.40%
Jun 27, 2020 -62.30%
Mar 28, 2020 3.60%
Dec 28, 2019 17.70%